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ABSTRACT
Purpose: Hypermethylation of promoter CpG islands (CIMP) has been strongly 
implicated in chemotherapy resistance and is implicated in the pathogenesis of a 
subset of colorectal cancers (CRCs) termed CIMP-high. 
Experimental Design: This phase I/II study in CRC (phase II portion restricted 
to CIMP-high CRC), treated fluoropyrimidine/oxaliplatin refractory patients with 
azacitidine (75 mg/m2/day subcutaneously D1-5) and CAPOX (capecitibine and 
oxaliplatin) every three weeks. 
Results: Twenty-six patients (pts) were enrolled in this study: 15 pts (12 treated 
at MTD) in phase I and 11 pts in phase II. No dose limiting toxicities were observed. 
A total of 14 pts were CIMP-high. No responses were seen. CIMP-high status did not 
correlate with efficacy endpoints [stable disease (SD) or progression-free survival 
(PFS)] or baseline vimentin methylation level. Changes in vimentin methylation over 
time did not correlate with efficacy outcomes. Baseline methylated vimentin correlated 
with tumor volume (P<0.001) and higher levels of baseline methylation correlated 
with the obtainment of stable disease (P=0.04). 
Conclusions: Azacitidine and CAPOX were well tolerated with high rates of stable 
disease in CIMP-high pts, but no objective responses. Serum methylated vimentin 
may be associated with benefit from a regimen including a hypomethylation agent, 
although this study is not able to separate a potential prognostic or predictive role 
for the biomarker. 
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INTRODUCTION
Epigenetic modification of gene expression 
represents a unique mechanism of oncogenic alteration 
that can lead to widespread changes in gene expression. 
Suppression of key gene targets such as tumor suppressors, 
represents an early and critical event in carcinogenesis. [1] 
DNA methyltransferases are responsible for this process 
by the addition of a methyl group to the 5’ position of 
cytosines, generally in the context of “CpG” dinucleotide 
sequences. Hypermethylation of such sequences in the 
context of gene promoters results in the suppression 
of transcription. One established subset of colorectal 
cancer has been characterized by the presence of aberrant 
DNA methylation at CpG island promoters (CpG island 
methylator phenotype, CIMP). In contrast to the majority 
of CRCs, which demonstrate widespread chromosomal 
gains and loss, termed chromosomal instability (CIN), 
the majority of CIMP-high CRCs are characterized by 
chromosomal stability. [2] In addition the molecular 
profile of CIMP-high CRC is unique with both a high rate 
of mismatch repair deficiency, or microsatellite instability 
(MSI), and RAS pathway activation, KRAS or BRAF 
mutations. [3, 4] Clinicopathological features are unique 
for CIMP-high CRC with an association with serrated 
adenoma precursor lesions, female gender, and proximal 
colonic location. [4] 
In addition to the role of DNA methylation in CRC 
carcinogenesis, CIMP-high has been correlated with 
chemotherapy resistance in not only CRC but also other 
tumor types. [6, 9] The acquired resistance to a variety of 
chemotherapy agents has been correlated with epigenetic 
changes in a variety of in vitro and in vivo models. [10] 
In colorectal cancer cell lines and xenografts the use of 
either the hypomethylator agent decitabine or azacitidine 
was demonstrated to reverse 5-FU resistance. [11, 12] The 
resistance to platinum-based chemotherapy in ovarian 
cancer has been correlated with the development of MLH1 
methylation, which was demonstrated to be reversible with 
the use of the demethylating agent decitabine. [13, 14] 
A recent in vitro study has also demonstrated the ability 
of chemotherapy, and in particular platinum agents, to 
synergistically increase the hypomethylation of decitabine. 
[15] 
Though single agent activity of hypomethylators 
in solid tumors as opposed to hematological cancers, 
has not been well demonstrated, recent clinical trials 
using epigenetic modulation in combination with 
chemotherapy have demonstrated the ability to restore 
chemotherapy sensitivity. [16-18] In particular in one 
study investigating platinum refractory ovarian cancer, 
the addition of azacitidine at 75mg/m2/days for 5 days in 
conjuncture with carboplatin every 4 weeks demonstrated 
partial responses in 4 and stable disease in 10 out of 20 
treated patients. [17] More recently the combination of 
azacitidine and entinostat, a histone deacetylase (HDAC) 
inhibitor demonstrated a 4% response rate in non-small 
cell lung cancer, and interestingly 4 of the 19 patients 
who underwent subsequent anticancer systemic therapy 
demonstrated objective responses. [19]
We have previously developed a methodology 
termed methyl-BEAMing that allows for the quantification 
of methylated DNA fragments from a patients’ blood. 
[20] When applied to vimentin, a gene preferentially 
methylated in colorectal cancer, the presence of 
methylated vimentin (1 fragment in 2 ml of plasma) was 
strongly correlated with colorectal cancer with an area 
under the receiver operating curve of 0.95 for patients with 
stage IV CRC compared to healthy adults. [20-22] Thus, 
methyl-BEAMing for methylated vimentin represents a 
quantitative means of interrogating the methylation status 
of CRC tumor DNA from the peripheral blood.
In this study we hypothesized that the use of 
azacitidine would restore fluoropyrimidine and oxaliplatin 
chemotherapy sensitivity, and that this effect would be 
predominantly seen in CIMP-high CRC, in which DNA 
hypermethylation is known to be highly active and plays 
a critical role in carcinogenesis. In addition, we explored 
the role of methylated vimentin as a potential biomarker 
for epigenetic modulation in CRC.
RESULTS
Baseline characteristics
This study enrolled 26 patients from 8/2010 to 
12/2012: 15 in the phase I portion and 11 in the phase 
II portion, Table 1. No dose-limiting toxicities (DLTs) 
occurred. Three patients were treated at the starting dose 
level and 12 at the highest dose level (subcutaneous 
azacitidine 75mg/m2/day days 1 to 5, intravenous 
oxaliplatin 110mg/m2 day 2, and oral capecitabine 
1500mg/m2 divided twice daily for 2 weeks every three 
weeks) or maximum tolerated dose (MTD). The additional 
6 patients at the MTD were enrolled due to concerns 
related to the potential for delayed hematological toxicity, 
which was not observed.
A total of 14 patients (3 patients in the phase 
I cohort) and 11 patients in the phase II cohort were 
CIMP-high. CIMP status was unknown in one patient. 
Prior progression on oxaliplatin-based therapy was 
retrospectively determined to meet Response Evaluation 
Criteria in Solid Tumors (RECIST) criteria in 81% of 
patients. The median number of cycles administered was 
4.5 (range: 1-11).
Toxicity
Common grade 3 or 4 toxicities and all toxicities 
occurring in > 20% of patients are shown in Table 2. The 
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most common grade 3 or 4 toxicities were neutropenia 
(38%), anemia (12%), diarrhea (12%), and oxaliplatin 
hypersensitivity reaction (12%).
Efficacy
All patients were evaluable for response assessment. 
No responses were seen. The study closed following the 
enrollment of 11 patients in the phase II cohort due to 
the prespecified futility boundary required one response 
in the first 11 treated patients. Stable disease occurred in 
17 patients (65%) with a median duration of 4.5 months 
(range 2.4 to 9m). Stable disease lasting for > 6 months 
was seen in 4 patients of whom 2 were CIMP-high. Stable 
disease occurred in 11 CIMP-high and 6 non-CIMP 
patients, P = 0.22. A waterfall plot is shown in Figure 1A 
and a spider plot in Supplemental Figure 1. The median 
progression-free survival (PFS) and overall survival (OS) 
for all patients was 3.7 and 9.5 months, respectively, 
(Figure 1B + 1D). There was no correlation between 
CIMP-high status and either PFS or OS, Figure 1C + 1E.
Post-progression therapy
Post-treatment median OS was 5.7m. Thirteen 
patients received subsequent post-study treatment with 
best RECIST response of progressive disease in 11 
patients and stable disease in 2 patients (Table 3). The 
median PFS for these 13 patients was 1.8 months. Of 
the 4 patients with > 6months of stable disease on study, 
2 did not receive subsequent therapy, 1 demonstrated 
progression to regorafenib, and 1 demonstrated stability 
to regorafenib lasting 14.6 months.
Vimentin methylation correlates with CIMP-high 
status and azacitdine modulates tumor vimentin 
methylation in vitro and in vivo
As the methylation status of vimentin in relation 
to CIMP-high status has not been evaluated, we 
evaluated the vimentin methylation from 574 CRC 
(218 with HumanMethylation27 BeadChip and 356 
with the HumanMethylation450 BeadChip) samples 
from the Cancer Genome Atlas (TCGA) Research 
Network. Although vimentin methylation was detected 
in the majority of colon cancers we found a statistically 
Table 1: Baseline characteristics (N=26)
Characteristics Number of Patients (%) 
Median age, years [range] 60, [34-78] 
Female Gender 11 (42%)
Poorly differentiated 3 (12%)
ECOG Performance Status 0-1 26 (100%)
 CIMP-high 14 (54%)
2 markers 7
3-6 markers 7
Braf V600E mutation 2 (8%)
Kras mutation 17 (65%)
Metastatic sites
Liver 13 (50%)
Lung 16 (62%)
Peritoneum 6 (23%)
Non-regional lymph nodes 5 (19%) 
Median Prior lines of therapy [range] 4.5 [2-9]
Prior oxaliplatin progression
RECIST progression 21 (81%)
Non-RECIST criteria progression 5 (19%)
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Table 2: Grade 2-4 toxicity
Hematologic Toxicities Grade 2 Grade 3 Grade 4
Neutropenia 4 7 3
Anemia 5 3
Thrombocytopenia 3 1
Non-hematologic Toxicities Grade 2 Grade 3 Grade 4
Fatigue 14
Neuropathy 1
Nausea 4 2
Diarrhea 3 3
Vomiting 2 2
Oxaliplatin hypersensitivity reaction 1 3
Anorexia 7 1
 
Dehydration 3 2  
Figure 1: Efficacy results for the combination of CAPOX and azacitidine. A. Radiographic best response stratified by CIMP 
status, with single case of unknown CIMP status represented by hashed bars. B. Progression-free survival for all patients. C. Progression-
free survival stratified by CIMP status (n = 25). D. Overall survival for all patients. E. Overall survival stratified by CIMP status (n = 25).
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significant increase in level of methylated vimentin 
in patients with CIMP-high CRC, P < 0.001 (Figure 
2). For all samples the median Beta value for vimentin 
methylation was 0.58 for CIMP-high patients and 0.41 for 
non-CIMP patients. To determine the ability of azacitidine 
to modulate vimentin methylation levels we treated the 
CIMP-high CRC cell line, HT-29, and two CIMP-high 
CRC patient derived xenograft (PDX) samples. In all 
cases a significant reduction in tumor methylated vimentin 
was seen between treated and non-treated samples, P < 
0.01 (Figure 3A). However, despite vimentin methylation 
modulation, HT-26 cell count and PDX tumor volume 
did not show statistical reductions with single agent 
azacitidine treatment (Figure 3B-3D).
Baseline methylated vimentin correlates with 
tumor volume and tumor response
A baseline plasma sample was available for 25 
patients and the mean, median, and range of methylated 
vimentin were 4.2%, 14.2%, and 0.1% to 89.3%, 
respectively. A total of 10 patients had baseline levels 
< 1% (3 with CIMP-high and 6 with non-CIMP, 1 with 
CIMP status unknown). Total baseline tumor volume 
was calculated for 23 patients; volumes could not be 
calculated for 3 patients with peritoneal carcinomatosis. 
Baseline plasma methylated vimentin correlated with 
tumor volume, R = 0.75, P < 0.0001, Figure 4A. After 
normalizing baseline vimentin methylation by tumor 
volume, increased baseline plasma methylated vimentin 
showed a statistically significant correlation with the 
occurrence of disease stability on therapy, P = 0.04, Figure 
4B
Baseline plasma methylated vimentin did not 
correlate with overall survival, P = 0.74. Adjusting for 
tumor volume there was no correlation between baseline 
plasma methylated vimentin and tumor CIMP status, P = 
0.88. Figure 4C. 
Changes in methylated vimentin over time
The percent change in methylated vimentin during 
therapy for the 15 patients with baseline values > 1% is 
shown in Figure 4D. Patients with baseline methylated 
vimentin < 1% were more likely to have progressive 
disease as best response, although the trend was not 
significant, P = 0.09. Methylated vimentin decreased 
in 9 of 15 patients at C2D1 with a median reduction of 
9.2% (range: -96.3% to 134.2%). Changes in methylated 
vimentin from baseline and either C1D5 or C2D1 did not 
Table 3:  Post-progression therapy for 13 patients treated following clinical trial completion
Study 
Number CIMP Status Post-Progression Therapy
Time from Azacitdine 
study completion to next 
treatment (days)
Best Response Time to progression (days)
3 CIMP-High 5-FU + Oxaliplatin + Bevacizumab + Cetuximab 19 PD 61
21 CIMP-High Erlotinib 1 PD 60
19 CIMP-High Irinotecan 1 PD 76
24 CIMP-High Regorafenib 29 PD 46
25 CIMP-High Regorafenib 22 PD 44
26 CIMP-High Regorafenib 1 SD 439
11 non-CIMP AMG 208 (c-MET inhibitor) 32 PD 34
12 non-CIMP Bevacizumab + Lenalidomide 51 PD 55
7 non-CIMP Cetuximab + Erlotinib + Bevacizumab 52 SD 111
13 non-CIMP Erlotinib + Bortezomib 32 PD 60
14 non-CIMP FOLFOX + Cetuximab + Dasatinib 40 PD 60
6 non-CIMP GDC-0449 (hedgehog inhibitor) 61 PD 45
9 Unknown Irinotecan + Bevacizumab + Cetuximab 26 PD 45
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correlate with disease stability. A reduction in methylated 
vimentin at C2D1 did correlate with a reduction in global 
DNA methylation at both C1D5 (-8.8% vs. -1.5%, P 
= 0.01) and C2D1 (-2.5% vs. -0.2%, P = 0.05). At the 
time of progression methylated vimentin was increased 
in 9 of 15 patients (median 15.3%, range: -99.3% to 
2068%). Interestingly all 6 patients with an initial 
increase in methylated vimentin at C1D5 demonstrated 
stability, whereas 3 of 6 patients with a decrease at C1D5 
demonstrated best response of progression. 
CAPOX/Azacitdine demethylates peripheral 
blood mononuclear cells (PBMCs)
Global DNA methylation was reduced from pre to 
post-treatment at all timepoints. The greatest reductions 
occurred at the day 5 timepoint for cycle 1 (median -8%, 
range -18.3% to 3.3%) and cycle 2 (median -7.4%, range 
-21.2% to 4%). The reduction at C2D1 was less with a 
median reduction of 0.6% (range -6.6% to 5.6%). Changes 
in global methylation did not correlate with the chance of 
obtaining SD at any time point.
DISCUSSION
This study reports for the first time the results 
of combining azacitidine with a standard cytotoxic 
chemotherapy combination for colorectal cancer, CAPOX. 
The results show the safety of this combination and note 
a high rate of stable disease. More interestingly this study 
investigated a possible blood based epigenetic biomarker, 
methylated vimentin, and suggests that baseline circulating 
levels of tumor methylation may represent a prognostic 
and/or predictive biomarker.
Biomarkers for epigenetic therapy in solid tumors 
have remained elusive with a number of studies finding 
minimal to no correlation between peripheral mononuclear 
cell methylation status and tumor methylation status. 
[23, 24] In one particular study investigating the effects 
of decitabine in solid tumors, pre and post global DNA 
methylation of CpG islands demonstrated no correlation 
between PBMC and tumor samples, r = 0.22, and no 
correlation for the change in DNA methylation, r = 0.02. 
[23] 
In this study we chose to use a gene, vimentin, in 
which increases in methylation have demonstrated a strong 
correlation with the development of colon cancer, and that 
Figure 2: Vimentin methylation correlates with CIMP-high status. The percentage of vimentin methylation (Beta-value) for 
574 CRC cases (218 with HumanMethylation27 BeadChip and 356 with the HumanMethylation450 BeadChip) from the Cancer Genome 
Atlas (TCGA) Research Network was statistically correlated with the presence of CIMP-high status (CIMP). All values are shown with the 
box representing 25-75% percentiles and median represented as a line.
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has been used as the target for a commercialized fecal 
DNA methylation diagnostic test (ColoSure, LabCorp). 
Our findings demonstrate that baseline increased 
circulating methylated vimentin correlates with greater 
tumor bulk. In addition, circulating methylated vimentin 
adjusted for radiographic tumor bulk correlated with a 
higher likelihood of obtaining stable disease. Though 
limited by sample size, this finding suggests that CRC with 
greater methylation extent, using vimentin methylation 
as the surrogate, appear to be more responsive to the 
combination of chemotherapy and a hypomethylating 
agent. Despite our hypothesis that this biomarker would 
demonstrate higher levels of methylation in patients with 
CIMP-high status, this was not seen in our clinical trial 
patient samples. Such findings suggest that methylated 
vimentin is not exclusively a CIMP-high phenomenon. 
These findings agree with the use of methylated vimentin 
as a marker across all CRC subtypes. 
This study did not find evidence to support the use 
of plasma methylated vimentin as a pharmacodynamic 
marker for azacitidine. In part, this reflects the small 
sample size within this study, only 15 patients had 
baseline samples with methylated vimentin at > 1%, and 
the large variations in methylated vimentin that were 
seen over time. Prior studies investigating pre and post 
tumor biopsies changes in promoter gene methylation 
have not correlated with efficacy outcomes. [23-26] These 
findings and our finding may reflect the challenge of drug 
delivery in solid tumors and the S-phase specific action of 
hypomethylating agents, in which incorporation into DNA 
is limited to only those tumors with high proliferation. 
In addition, our findings are confounded by the role of 
increased methylated vimentin as both a marker of tumor 
burden and likely also a marker of tumor cytotoxicity. 
A limited number of clinical trials have investigated 
either global or gene specific DNA methylation changes 
from plasma or serum as potential pharmacodynamic 
biomarkers of epigenetic therapy. [16, 19, 25] Though 
Figure 4: Correlation of baseline circulating methylated vimentin with tumor volume and tumor response status. A. 
Correlation plot between tumor volume and percent circulating methylated vimentin. Tumor volume statistically correlated with percent 
circulating methylated vimentin. The dashed line represents the line of best fit from ordinary least squares regression model with a Pearson 
correlation coefficient of 0.75. Diamonds represent stable disease patients and circles represent progressive disease patients. B.-C. The 
baseline percent circulating methylated vimentin normalized by baseline tumor volume was stratified by CIMP status and tumor response 
to CAPOX and azacitidine, respectively. All values are shown with the box representing 25-75% percentiles and median represented as 
a line. Two-tailed paired t test use for p-value (N = 22). D. Individual patient data for the percent of circulating methylated vimentin for 
cases with baseline methylation > 1% (N = 15). 
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changes in methylation were seen in all studies, occurring 
in 100%, 50%, or 38% of cases, respectively, only one 
study found a correlation between gene hypomethylation 
and clinical outcomes. In this clinical trial investigating 
azacitidine and entinostat in non-small cell lung cancer 10 
out of 26 patients demonstrated promoter hypomethylation 
of at least 2 out of 4 target genes. [19] In these 10 patients 
both PFS and OS were statistically improved. 
Two recent clinical trials have suggested improved 
chemotherapy and targeted therapy responsiveness 
following epigenetic therapy. [19, 27] In contrast to these 
two reports we did not see any evidence for increase 
activity following our study with 11 of 13 patients 
demonstrating progression on their next line of therapy.
In this study azacitdine was dosed as 75mg/m2 
daily for 5 days every three weeks, which is similar to 
the current approved dose in myelodysplastic syndrome 
of 75mg/m2 daily for 7 days every 4 weeks. The optimal 
dose and dosing schedule for azacitdine in solid tumors 
has not been identified, but both in vitro and clinical data 
have demonstrated that lower drug levels are able to 
provide adequate hypomethylation and clinical benefit in 
hematological malignancies. [28-30] Whether improved 
hypomethylation and greater clinical activity would have 
been seen from a lower more continuous dosing schedule 
is not known. In addition the lack of on-treatment tumor 
biopsies represents a limitation of this study. Despite 
the preclinical data demonstrating clear modulation of 
vimentin with azacitdine, it is still unclear the impact of 
azacitidine on actual tumor tissue. 
In conclusion we demonstrate the safety of 
combining azacitidine with capecitabine and oxaliplatin 
in colorectal cancer. This clinical trial did not validate 
the use of CIMP-high status as a predictive biomarker 
for azacitdine. In addition evidence to support the use 
of plasma methylated vimentin as a pharmacodynamic 
marker for azacitdine was not seen. Pre-treatment 
circulating methylated vimentin correlated with both 
Figure 3: A. Azacitidine reduces tumor vimentin methylation but not tumor size in the CIMP-high HT-29 CRC cell line and two CIMP-
high CRC patient derived xenografts (PDXs). A. Pre and post azacitidine treatment samples were analyzed for the vimentin methylation 
status by the Illumina Infinium HumanMethylation450 BeadChip array. CIMP-high HT29 CRC cells were treated with and without 
continuous azacitidine (1 uM) for 2 weeks and then counted. Two CIMP-high PDXs were treated with phospho-buffered saline control or 
0.5 mg/kg azacitidine administered intraperitoneal twice weekly for two generations in NOD-SCID-gamma mice, and tumor measurements 
were recorded twice weekly. B. Cell counts for CIMP-high HT-29 CRC cell line with or without azacitidine treatment. C.-D. The tumor 
volume for two CIMP-high PDXs with or without azacitidine treatment. Bars represent 95% confidence intervals.
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tumor bulk and the obtainment of clinical benefit for 
study treatment. Further work exploring both alternative 
epigenetic schedules and combinations, and the use of 
methylated vimentin as a predictor for epigenetic benefit 
in CRC are needed.
MATERIALS AND METHODS
Patients
This is an open-label, single-institution, phase I/
II study of azacitidine and capecitabine and oxaliplatin 
(CAPOX) for histologically confirmed colorectal 
adenocarcinoma. Eligibility criteria required Eastern 
Cooperative Oncology Group (ECOG) performance 
status of ≤ 2, adequate organ function, measurable 
disease, peripheral neuropathy ≤ 2 grade 2, and refractory 
to fluoropyrimidine and oxaliplatin therapy (defined 
as either clinical or radiographic progression on or 
within 3 months of treatment). In addition for the phase 
II portion, enrollment was restricted to CIMP-high 
patients, which was defined as hypermethylation at ≥ 
2 of 6 methylation-specific polymerase chain reaction 
(PCR) markers (hMLH1, P16, P14, MINT1, MINT2, and 
MINT31). CIMP testing was performed at University of 
Texas MD Anderson Cancer Center (UTMDACC) in a 
CLIA-certified manner (Supplemental Table 1). [7] This 
study was conducted with approval by the UTMDACC 
Institutional Review Board, and all participants provided 
written informed consent (NCT01193517).
Study design and treatment
A 3+3 design was utilized for the phase 1 portion 
followed by a phase II expansion at the MTD. The starting 
dose level was subcutaneous azacitidine 75mg/m2/day 
days 1 to 5, intravenous oxaliplatin 90mg/m2 day 2, and 
oral capecitabine 1500mg/m2 divided twice daily for 2 
weeks every three weeks. A single dose escalation level 
(+1) existed, in which oxaliplatin was increased to 110mg/
m2. Restaging was conducted every three cycles.
Dose limiting toxicities (DLTs), according to the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events Version 4.0, were defined as any of the 
following toxicities that occurred during the first treatment 
cycle: drug related ≥ grade 3 non-hematological toxicity 
(excluding correctable grade 3 nausea, vomiting, diarrhea, 
electrolyte, and glucose abnormalities), grade 4 anemia, 
grade 4 thrombocytopenia, grade 4 neutropenia for > 5 
days, ≥ grade 3 febrile neutropenia, or a treatment delay 
of > 14 days.
 Cell line and patient derived xenograft (PDX)
The CIMP-high colorectal cancer cell line HT29 
(from the American Type Culture Collection) was 
maintained in DMEM-F12 supplemented with 10% fetal 
bovine serum and 2 mM L-glutamine. [31] Short tandem 
repeat DNA profiling was done approximately 6 months 
prior to treatment to confirm HT-29 identity. The cells were 
seeded in 6 well plates, allowed to attach for 24 h at 37°C. 
Thereafter half HT29 cells were continuously exposed to 1 
uM azacitidine for 2 weeks. During treatment, azacitidine 
(Sigma-Aldrich) was freshly prepared daily with new 
growth medium at 1 uM and the growth medium was 
replaced with new medium with (treated cells) or without 
(parental cells) azacitidine. The cells were subcultured 
until the attached cells reached 70% confluence. At the end 
of treatment, cells were counted and collected for DNA. 
All analyses were done in triplicate.
Biopsy specimens from tumors of two separate 
patients with MLH-1 methylated CIMP-high metastatic 
colorectal cancer were implanted into the subcutaneous 
flanks of female NOD-SCID-gamma mice in order to 
establish PDX models. Upon successful uptake of the 
tumor, mice were randomized in an initial generation to 
receive a phospho-buffered saline control or 0.5 mg/kg 
azacitidine administered intraperitoneal twice weekly. 
Once the tumor volume reached 1500 mm3 in size, mice 
were sacrificed, and the tumors were split and expanded 
into a second generation of female NOD-SCID-gamma 
mice in order to maximize the exposure time of the 
demethylating agent to the tumor. Mice continued to 
receive phosphate-buffered saline control or azacitdine 
(0.5 mg/kg) according to the treatment administered 
for the prior generation of the given tumor. Tumor 
measurements were recorded twice weekly. At the end of 
treatment each arm had at least 3 separate tumors for final 
tumor size assessment and DNA collection. 
Tumor methylation analysis
The CIMP and vimentin methylation status 
for 574 CRC cases (218 with the Illumina Infinium 
HumanMethylation27 BeadChip and 356 with the 
Illumina Infinium HumanMethylation450 BeadChip) 
from TCGA Research Network (http://cancergenome.nih.
gov/) were analyzed. The sequences within the human 
genome that corresponded to the PCR primers for the 6 
CpG islands analyzed in the clinical trial (hMLH1, p16, 
p14, MINT1, MINT2, and MINT31) were identified using 
BiSearch (http://bisearch.enzim.hu/). [32, 33] Using NCI 
Blast the corresponding nucleotide locations within the 
Genome Reference Consortium Human genome build 
37 (GRCh37) were correlated with the CpG islands from 
the HumanMethylation450 array (Supplemental Table 
2A-B). Within the PCR amplified regions of hMLH1, 
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MINT2, and MINT31, 1-2 CpG islands were identified, 
while for MINT1, p14, and p16 1-2 CpG islands were 
only identified < 300 nucleotides adjacent from each 
of the primer pairs. For each CpG island the beta-value 
was converted to an M-value and the distribution of 
M-values from the TCGA dataset was plotted and found 
to be bimodal (Supplemental Table 3A-B). [34] The rate 
of methylation positivity for each marker was found to 
correlate well with clinically obtained CIMP testing and 
> 2 methylated markers was used to define CIMP-high. 
CpG islands from the HumanMethylation27 BeadChip 
could not be aligned with the clinical CIMP PCR primers, 
and thus for this cohort a clustering method of methylation 
profiles was used as previously described. [35]
Pre and post azacitidine treatment samples from 
HT-29 and the two PDX samples were analyzed by the 
Illumina Infinium HumanMethylation450 BeadChip array 
and methylated vimentin status determined by analysis of 
the three methylation probes correlating with exon 1 of 
vimentin. Methylation of exon 1 was chosen to align with 
prior work investigating vimentin methylation status. [20-
22]
Plasma vimentin and peripheral blood 
mononuclear cell (PBMC) methylation analyses
Blood samples were collected at baseline, cycle 
1 day 5 (C1D5), cycle 2 day 1 (C2D1), cycle 2 day 5 
(C2D5), and at each restaging. Samples were processed 
within 2 hours in Cell Preparation Tubes (BD, Franklin 
Lakes, NJ). Plasma and pbmcs were separated after 
a single centrifugation step and stored at -80oC until 
analysis. 
For circulating cell-free vimentin methylation DNA 
was purified and extracted from 2 ml plasma aliquots. 
Methylated vimentin status of exon 1 was determined by 
bisulfite conversion, PCR amplification of the vimentin 
differentially methylated domain with bisulfite specific 
methylation indifferent primers [20], and analysis of the 
methylation status of the amplicon by Next Generation 
bisulfite sequencing. Individual sequence reads were 
classified as methylated if methylation was detected at 
greater than or equal to 5 of the 10 CpGs on the amplicon, 
and the percent of methylated vimentin reads in circulating 
DNA was determined for each sample. 
For global DNA methylation of PBMC, DNA was 
isolated and treated with bisulfite. LINE1 methylation 
assay coupled with pyrosequencing was then utilized. [36, 
37].
Statistical analysis
The phase I primary endpoint was to determine 
MTD and the phase II primary endpoint was response rate 
by RECIST v1.1. The phase II sample size was 30 patients 
to ensure that the posterior 90% credibility interval will be 
(11%, 35%), under the assumption of a 20% response rate. 
Phase II early stopping rules required ≥ 1 response in the 
first 11 patients. 
In a retrospective manner the previously determined 
oxaliplatin progression prior to study entry and post-study 
treatment response were determined by RECIST v1.1 
criteria. Tumor volumes were calculated using computed 
tomography scans using Voxtool (version 3.0.64z, General 
Electric Corp., Fairfield, CT). 
Descriptive statistics for continuous (mean, median, 
and range) and categorical variables (frequency and 
percentage) are reported. Fisher’s exact test and Wilcoxon 
rank-sum test were used for categorical and continuous 
variables, respectively. Ordinary least squares regression 
and Pearson’s product-moment correlation coefficient 
were used to assess linear relationships. Survival was 
estimated using the Kaplan-Meier method. The two-sided 
log-rank test was used to assess group differences in 
survival endpoints. All P values presented are two-sided 
and statistical significance is P ≤ 0.05.
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